ribociclib
novartis
['maintain trial', 'ribociclib', 'breast']
maintain trial presented at #asco22 shows progression-free survival benefit to ribociclib+switching hormone therapy (5.29mo) compared to placebo (2.76mo) for patients with hr+, her2-negative #metastatic #breastcancer 
A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally.
https://t.co/dvoS7vv1mZ